½ÃÀ庸°í¼­
»óǰÄÚµå
1395011

Àΰø ÃéÀå µð¹ÙÀ̽º ½Ã½ºÅÛ(APDS) ½ÃÀå : µð¹ÙÀ̽º À¯Çüº°, ÃÖÁ¾ ¿ëµµº° - ¼¼°è ¿¹Ãø(2023-2032³â)

Artificial Pancreas Device Systems (APDS) Market - By Device Type (Threshold Suspend Device Systems, Control-to-range (CTR) Systems, Control-to-target (CTT) Systems), By End-use (Hospitals and Clinics, Homecare) - Global Forecast, 2023-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Àΰø ÃéÀå µð¹ÙÀ̽º ½Ã½ºÅÛ(APDS) ½ÃÀåÀº ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß ³ë·Â¿¡ ÀÇÇÑ À¯¸ÁÇÑ ¼º°ú¿¡ ÀÇÇØ Áö¿øµÇ¸ç, 2023-2032³â¿¡ CAGR 8.8%¸¦ ±â·ÏÇÕ´Ï´Ù. ȹ±âÀûÀÎ ¿¬±¸ ¼º°ú´Â ´ç´¢º´ °ü¸®¿¡¼­ ÀÌ ½Ã½ºÅÛÀÇ À¯È¿¼ºÀ» ³ªÅ¸³»´Â °ÍÀ̸ç, ȯÀÚ ÄɾîÀÇ °­È­¿¡ Èñ¸ÁÀ» ÁÖ´Â °ÍÀÔ´Ï´Ù.

¿¹¸¦ µé¾î 2023³â 3¿ù ¹Ì±¹³» 3°³ ¼Ò¾Æ´ç´¢¼¾ÅÍ¿¡¼­ 13ÁÖ µ¿¾È ÁøÇàµÈ ¼Ò¾Æ ÀΰøÃéÀå(PEDAP) ½ÃÇèÀº ÀΰøÃéÀå ±â¼úÀÌ 2-5¼¼ 1Çü ´ç´¢º´ À¯¾ÆÀÇ Ç÷´ç Á¶ÀýÀ» Çâ»ó½ÃŲ´Ù´Â »ç½ÇÀ» ¹àÇô³Â½À´Ï´Ù. ¹Ì±¹ ±¹¸³´ç´¢º´-¼ÒÈ­±â-½ÅÀ庴 ¿¬±¸¼Ò(NIDDK)ÀÇ Áö¿øÀ¸·Î ÁøÇàµÈ ÀÌ ¿¬±¸ °á°ú´Â New England Journal of Medicine¿¡ °ÔÀçµÇ¾ú½À´Ï´Ù. Æó¼âÇü ·çÇÁ Á¦¾î¶ó°íµµ ºÒ¸®´Â ÀÌ ±â¼úÀº ÅëÇÕ ´ç´¢º´ °ü¸® ½Ã½ºÅÛ ¿ªÇÒÀ» Çϸç, Áö¼ÓÀûÀÎ Æ÷µµ´ç ¸ð´ÏÅ͸µ(CGM)À» ÅëÇØ Æ÷µµ´ç ¼öÄ¡¸¦ ÃßÀûÇϰí Çʿ信 µû¶ó Àν¶¸° ÆßÇÁ¸¦ ÅëÇØ Àν¶¸°À» ÀÚµ¿À¸·Î Åõ¿©ÇÕ´Ï´Ù.

ÀÓ»ó½ÃÇè¿¡¼­ ÁÁÀº °á°ú°¡ ³ª¿À¸é¼­ APDS¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Àν¶¸° Åõ¿©¸¦ ÀÚµ¿È­Çϰí Ç÷´ç ¼öÄ¡¸¦ À¯ÁöÇÏ´Â ±â¼úÀÇ ÀáÀç·ÂÀÌ ÁÖ¸ñ¹ÞÀ¸¸é¼­ APDS´Â ´ç´¢º´ °ü¸®ÀÇ Çõ½ÅÀÇ ÀÌÁ¤Ç¥·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³«°üÀûÀÎ Àü¸ÁÀº ¼¼°è ´ç´¢º´ Ä¡·áÀÇ Çõ½ÅÀ» À§ÇÑ Àΰø ÃéÀå µð¹ÙÀ̽º ½Ã½ºÅÛ(APDS) ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Á¦¾î ¹üÀ§(CTR) ±â±â ºÎ¹®Àº 2023-2032³â Å« ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸ñÇ¥ ¹üÀ§ ³»¿¡¼­ Á¤È®ÇÑ Ç÷´ç °ü¸®¸¦ Á¦°øÇÏ´Â ÀÌ Çõ½ÅÀûÀÎ ½Ã½ºÅÛÀº ´ç´¢º´ Ä¡·á¸¦ ÀçÁ¤ÀÇÇϸç, CTR ±â¼úÀº ÃÖÀûÀÇ Ç÷´ç ¼öÁØÀ» º¸ÀåÇϰí ÀúÇ÷´ç ¹× °íÇ÷´ç À§ÇèÀ» ÁÙÀÔ´Ï´Ù. Áö¼ÓÀû Ç÷´ç ¸ð´ÏÅÍ(CGM)ÀÇ ½Ç½Ã°£ µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î Àν¶¸° Åõ¿©¸¦ ¹Ì¼¼ Á¶Á¤ÇÒ ¼ö ÀÖ´Â CTR Àåºñ´Â ´ç´¢º´ °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. »çȸÀû ÃéÀå ½Ã½ºÅÛ ½ÃÀå ¸ÅÃâÀº ´ç´¢º´ ȯÀÚÀÇ °Ç°­ »óÅ °³¼±°ú »îÀÇ Áú Çâ»óÀ» ±â´ëÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ Ã·´Ü ½Ã½ºÅÛ¿¡ ´ëÇÑ ¸Å·ÂÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀçÅÃÄ¡·á ºÐ¾ß´Â 2023-2032³â ÁÖ¸ñÇÒ ¸¸ÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, APDS´Â ȹ±âÀûÀÎ º¯È­¸¦ °¡Á®¿Í °³ÀÎÀÌ Áý¿¡¼­ Æí¸®ÇÏ°Ô ÀÚ½ÅÀÇ »óŸ¦ °ü¸®ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. APDS´Â Áö¼ÓÀû Ç÷´ç ¸ð´ÏÅÍ¿Í ÀÚµ¿ Àν¶¸° Åõ¿©¸¦ ÀÌ¿ëÇÑ ÅëÇÕ ½Ã½ºÅÛÀ» ÅëÇØ ȯÀÚ°¡ º´¿øÀ» ¹æ¹®ÇÏÁö ¾Ê°íµµ ÃÖÀûÀÇ Ç÷´çÄ¡¸¦ À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â °³ÀÎÈ­µÇ°í Á¢±Ù °¡´ÉÇÑ Ä¡·á·ÎÀÇ ±Ùº»ÀûÀÎ º¯È­¸¦ ¹Ý¿µÇϸç, ÀçÅÃÄ¡·á°¡ Çö´ë ´ç´¢º´ °ü¸® Àü·«ÀÇ Ãʼ®ÀÌ µÇ¸é¼­ Àΰø ÃéÀå µð¹ÙÀ̽º ½Ã½ºÅÛ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

À¯·´ÀÇ Àΰø ÃéÀå ½Ã½ºÅÛ(APDS) ½ÃÀåÀº 2023-2032³â °ý¸ñÇÒ ¸¸ÇÑ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ªÀº APDS ±â¼úÀ» ¼ö¿ëÇϰí Ç÷´ç Á¶ÀýÀ» À§ÇÑ È¿À²ÀûÀ̰í ÀÚµ¿È­µÈ ¼Ö·ç¼ÇÀ» ã°í ÀÖ½À´Ï´Ù. ȯÀÚÀÇ °á°ú¿Í »îÀÇ Áú Çâ»ó¿¡ ÃÊÁ¡À» ¸ÂÃá APDS´Â Áö¼ÓÀûÀÎ Ç÷´ç ¸ð´ÏÅ͸µ°ú Àν¶¸° Åõ¿©¸¦ ÅëÇÕÇÏ¿© ÆíÀǼº°ú È¿°ú·Î Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù. À¯·´ ½ÃÀåÀÇ ¼ºÀåÀº Çõ½ÅÀûÀ̰í ȯÀÚ Áß½ÉÀûÀÎ ´ç´¢º´ Ä¡·á¿¡ ´ëÇÑ Ã·´ÜÀÎ Á¢±Ù ¹æ½ÄÀ» ¹Ý¿µÇϰí ÀÖÀ¸¸ç, À¯·´ Àü¿ª¿¡¼­ APDS ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 11¿ù À×±Û·£µå¿Í ¿þÀÏÁîÀÇ NHS´Â 1Çü ´ç´¢º´À» ¾Î°í ÀÖ´Â ¼ºÀΰú ¼Ò¾Æ ȯÀÚ 15¸¸ ¸í ÀÌ»ó¿¡°Ô Àΰø ÃéÀåÀ» Á¦°øÇÒ °èȹÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Àΰø ÃéÀå µð¹ÙÀ̽º ½Ã½ºÅÛ »ê¾÷ ÀλçÀÌÆ®

  • COVID-19ÀÇ ¿µÇ⠺м®
  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ±â¼ú »óȲ
  • ±ÔÁ¦ »óȲ
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© ¹× °úÁ¦
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
    • Medtronic Plc
    • Johnson & Johnson Services Inc
    • Tandem Diabetes Care, Inc.
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå Àΰø ÃéÀå µð¹ÙÀ̽º ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : µð¹ÙÀ̽º À¯Çüº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : µð¹ÙÀ̽º À¯Çüº°
  • ¿ªÄ¡ ÁßÁö µð¹ÙÀ̽º ½Ã½ºÅÛ
  • Control-to-range(CTR) ½Ã½ºÅÛ
  • Control-to-target(CTT) ½Ã½ºÅÛ

Á¦6Àå Àΰø ÃéÀå µð¹ÙÀ̽º ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : ÃÖÁ¾ ¿ëµµº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : ÃÖÁ¾»ç¿ëÀÚº°
  • º´¿ø¡¤Áø·á¼Ò
  • ÀçÅÃÀÇ·á
  • ±âŸ

Á¦7Àå Àΰø ÃéÀå µð¹ÙÀ̽º ½Ã½ºÅÛ ½ÃÀå ±Ô¸ð¡¤¿¹Ãø : Áö¿ªº°(2018-2032³â)

  • ÁÖ¿ä µ¿Çâ : Áö¿ªº°
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ±â¾÷ °³¿ä

  • Medtronic Plc
  • Johnson & Johnson Services Inc
  • Bigfoot Biomedical
  • Tandem Diabetes Care, Inc.
  • Pancreum, Inc.
  • TypeZero Technologies, LLC
  • Beta Bionics
  • Insulet Corporation
  • Defymed
  • Inreda Diabetic
  • Diabeloop
KSA 23.12.21

Global Artificial Pancreas Device Systems (APDS) Market will witness 8.8% CAGR between 2023 and 2032, propelled by promising outcomes from extensive research and development efforts. Breakthroughs showcase the efficacy of these systems in managing diabetes, offering hope for enhanced patient care.

For instance, in March 2023, The Pediatric Artificial Pancreas (PEDAP) Trial, a 13-week randomized controlled study across three pediatric diabetes centers in the United States, revealed enhanced blood glucose control in toddlers aged 2 to 5 with type 1 diabetes through Artificial Pancreas Technology. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the NIH, findings were published in the New England Journal of Medicine. This technology, also termed closed-loop control, acts as an integrated diabetes management system, utilizing continuous glucose monitoring (CGM) to track glucose levels and automatically administering insulin as necessary via an insulin pump.

As clinical trials demonstrate positive results, the demand for APDS grows. The technology's potential to automate insulin delivery and maintain glucose levels garners attention, positioning APDS as a beacon of innovation in diabetes management. This optimism fuels the artificial pancreas device systems (APDS) market expansion as it moves towards transforming diabetes care globally.

The overall Artificial Pancreas Device Systems (APDS) Market is classified based on device type, end-use, and region.

Control-to-range (CTR) devices segment will exhibit significant growth from 2023 to 2032. Offering precise glucose management within target ranges, these innovative systems redefine diabetes care. CTR technology ensures optimal blood glucose levels, mitigating both hypoglycemia and hyperglycemia risks. With their ability to fine-tune insulin delivery based on real-time data from continuous glucose monitors (CGM), CTR devices revolutionize diabetes management. The art of social pancreas device systems market revenue is propelled by the promise of improved health outcomes and enhanced quality of life for individuals navigating diabetes, amplifying the appeal of these advanced systems.

Homecare segment will register a noteworthy CAGR from 2023 to 2032. APDS offers a transformative shift, allowing individuals to manage their condition conveniently at home. With integrated systems utilizing continuous glucose monitors and automated insulin delivery, APDS empowers patients to maintain optimal blood glucose levels without hospital visits. This trend reflects a fundamental shift towards personalized, accessible care, driving the artificial pancreas device system market as home care becomes a cornerstone in modern diabetes management strategies.

Europe artificial pancreas device systems (APDS) market will showcase a commendable CAGR from 2023 to 2032. The region embraces APDS technology, seeking efficient, automated solutions for glucose control. With a focus on enhancing patient outcomes and quality of life, APDS integrates continuous glucose monitoring and insulin delivery, gaining traction for its convenience and efficacy. The market's growth in Europe reflects a progressive approach towards innovative, patient-centric diabetes care, fostering a rising demand for APDS solutions across the continent. For instance, in November 2023, The NHS in England and Wales planned to provide over 150,000 individuals, both adults and children with type 1 diabetes, with an artificial pancreas-a move praised by experts as revolutionary and life-saving.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & workings
  • 1.3 Forecast calculations
  • 1.4 Data Sources
    • 1.4.1 Primary
    • 1.4.2 Secondary
      • 1.4.2.1 Paid sources
      • 1.4.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Global artificial pancreas device systems market 360 degree synopsis, 2018 - 2032
  • 2.2 Regional trends
  • 2.3 Device type trends
  • 2.4 End-use trends

Chapter 3 Artificial Pancreas Device Systems Industry Insights

  • 3.1 COVID- 19 impact analysis
  • 3.2 Industry ecosystem analysis
  • 3.3 Technology landscape
  • 3.4 Regulatory landscape
  • 3.5 Industry impact forces
    • 3.5.1 Growth drivers
      • 3.5.1.1 Growing prevalence of diabetes
      • 3.5.1.2 Rising demand for automated systems for glycemic control
      • 3.5.1.3 Technological advancements in continuous glucose monitoring sensors
      • 3.5.1.4 Increasing research and development activities by key players
    • 3.5.2 Industry pitfalls & challenges
      • 3.5.2.1 High cost of device systems and safety concerns
      • 3.5.2.2 Stringent regulatory framework
  • 3.6 Growth potential analysis
    • 3.6.1 By device type
    • 3.6.2 By end-use
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Competitive analysis of major market players, 2022
    • 4.2.1 Medtronic Plc
    • 4.2.2 Johnson & Johnson Services Inc
    • 4.2.3 Tandem Diabetes Care, Inc.
  • 4.3 Competitive positioning matrix, 2022
  • 4.4 Strategic outlook matrix, 2022

Chapter 5 Artificial Pancreas Device Systems Market Size and Forecast, By Device Type, 2018-2032 (USD Million & Units)

  • 5.1 Key trends, by device type
  • 5.2 Threshold suspend device systems
  • 5.3 Control-to-range (CTR) systems
  • 5.4 Control-to-target (CTT) systems

Chapter 6 Artificial Pancreas Device Systems Market Size and Forecast, By End-use, 2018-2032 (USD Million)

  • 6.1 Key trends, by end-use
  • 6.2 Hospitals and clinics
  • 6.3 Homecare
  • 6.4 Others

Chapter 7 Artificial Pancreas Device Systems Market Size and Forecast, By Region, 2018-2032 (USD Million & Units)

  • 7.1 Key trends, by region
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pcific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
    • 7.5.4 Rest of Latin America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 South Africa
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East & Africa

Chapter 8 Company Profiles

  • 8.1 Medtronic Plc
  • 8.2 Johnson & Johnson Services Inc
  • 8.3 Bigfoot Biomedical
  • 8.4 Tandem Diabetes Care, Inc.
  • 8.5 Pancreum, Inc.
  • 8.6 TypeZero Technologies, LLC
  • 8.7 Beta Bionics
  • 8.8 Insulet Corporation
  • 8.9 Defymed
  • 8.10 Inreda Diabetic
  • 8.11 Diabeloop
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦